Glioma
Conditions
Keywords
Glioblastoma multiforme, DC vaccine, Mismatch repair, Microsatellite instability, Biomarker
Brief summary
Glioblastoma (GBM) is the most malignant primary intracranial tumor with a median survival of about 18 months, and new therapies are urgently needed. Tumor vaccines has been shown to improve survival of GBM, but not all patients can benefit from vaccine treatment and biomarkers are urgently needed. Deletion of mismatch repair (MMR) protein and microsatellite instability (MSI) state are important features in the biological evolution of GBM, and may be used as markers for tumor vaccine. Therefore, this project will collect samples from GBM patients before and after vaccine treatment respectively, and evaluate the role of MMR/MSI gene phenotype in predicting vaccine efficacy and the potential molecular mechanism. Moreover, MMR/MSI phenotypes will be assessed by deep-learning and radiomics using images to establish noninvasive markers for vaccine.
Interventions
BIOLOGICALDC vaccine
DC vaccine produced by the Team
Sponsors
Huashan Hospital
Study design
Observational model
OTHER
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
The patients with glioma in the Department of Neurosurgery of Huashan Hospital Affiliated to Fudan University who meet the following three conditions can be enrolled 1. They were 18-80 years old, male and female; 2. The pathological results of frozen section during operation were gliomas (20 cases of who grade II, II and IV, respectively); 3. Tissue (6 mm \* 6 mm) can be used for cell sorting on the basis of not affecting clinical routine diagnosis; 4. Sign informed consent.
Exclusion criteria
Patients who meet any of the following criteria will not be included in this study: 1. Participants in other clinical trials; 2. Pregnant women.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Transcriptomics | 36 months | The issues collected will be used for transcriptome sequencing to measure gene expression level. |
| Immunomics | 36 months | The issues collected will be used for TCR/BCR sequencing to measure clonality of lymphocytes |
| Proteomics | 36 months | The issues collected will be used for TCR/BCR sequencing to measure gene expression level in protein |
| Radiomics | 36 months | The features from images will be extracted using algorithm of Deep-learning or Radiomics |
| IHC analysis | 36 months | Different expression level of proteins (CD3,CD8,B7-H4, MMR proteins) in Gliomas with different grades and molecular subgroups (300 cases) will be measured using immunohistochemical. |
| Genomics | 36 months | The issues collected will be used for whole genome sequencing or whole exome sequencing to measure gene mutations. |
Countries
China
Contacts
Primary ContactDi Chen, MD
Outcome results
None listed